THE INFLUENCE OF COMPETITION DRUGS FOR THE TREATMENT OF HYPERTENSION IN PATIENTS WITH TYPE 2 DIABETES

Authors

  • V. I. Vdovichenko Львівський національний медичний університет імені Данила Галицького Кафедра терапії N1 і медичної діагностики ФПДО
  • V. V. Kulchytskyi Львівський національний медичний університет імені Данила Галицького Кафедра терапії N1 і медичної діагностики ФПДО

DOI:

https://doi.org/10.11603/2415-8798.2017.3.8089

Keywords:

diabetes mellitus type 2, arterial hypertension, competition of medicines, cytochrome P-450.

Abstract

The question of the effect of drug competition on the effectiveness of treatment of arterial hypertension (AH ) in type 2 diabetes mellitus (DM ) is very urgent and requires in-depth study. Until now, it has not been established how the prescription of drugs, taking into account their competition in the liver, will affect the achievement of target blood pressure in patients with type 2 diabetes. This was the reason for the study.

The aim of the study – to improve the achievement of target blood pressure in patients with type 2 diabetes mellitus.

Materials and Methods. The main group consisted of 35 patients with arterial hypertension and type 2 diabetes mellitus who received treatment at the Therapeutic Departments of the Lviv Municipal Emergency Hospital No. 1 and No. 2.

Results and Discussion. The control group consisted of 74 people with type 2 diabetes and hypertension who were treated without taking into account inter-drug competition in the cytochrome P-450 system. In 26 among 35 (74 %) patients in the main group treated with medicamental mediated by Cyp-450, the target blood pressure was achieved. In the control group, taking drugs without taking this interaction into account, the target blood pressure was achieved only in 33 patients (44.6 %). It has been established that the treatment of hypertension with type 2 diabetes, conducted taking into account the interaction of drugs in the cytochrome P-450 system, is significantly more effective than therapy without taking this interaction into account.

Conclusions. To optimize the correction of blood pressure in patients with type 2 diabetes, it is necessary to prescribe antihypertensive drugs that do not compete with hypoglycemic drugs in the liver.

Author Biographies

V. I. Vdovichenko, Львівський національний медичний університет імені Данила Галицького Кафедра терапії N1 і медичної діагностики ФПДО

Вдовиченко Валерій Іванович Львівський національний медичний університет імені Данила Галицького професор Пекарська, 69, Львів, Україна, 79010

V. V. Kulchytskyi, Львівський національний медичний університет імені Данила Галицького Кафедра терапії N1 і медичної діагностики ФПДО

Кульчицький Василь Володимирович Львівський національний медичний університет імені Данила Галицького аспірант Пекарська, 69, Львів, Україна, 79010

References

American Diabetes Association. Standards of medical care in diabetes (2014). Diabetes Care, (37), 1, 14-80.

Belpaire, F.M. & Bogaert, M.G. (1996). Cytochrome P450: genetic polymorphism and drug interactions. Acta Clinica Belgica, 51, 254-260.

Cupp, M.J. & Tracy, T.S. (1998). Cytochrome P450: new nomenclature and clinical implications. Am. Fam. Physician, 57, 107-116.

Department of Medicine Clinical Pharmacology P450 Drug Interaction Table Flockhart Table ™. Substrates. Retrieved from. http://medicine.iupui¬.edu/clinpharm¬¬/ddis/main-table/.

García-Donaire, J.A., Segura, J. & Cerezo, C. (2011). A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients. Blood Pressure, 20, 322-334.

Goodman, L.S., Limbird, L.E., Milnoff, P.B., Gilman, A.G. & Hardman, J.G. (Eds.) (1996). Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill.

Inzucchi, S.E., Bergenstal, R.M. & Buse, J.B. (2012). Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, (35), 1-16.

Perk, J., De Backer, G. & Gohlke, H. (2012). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart J., 33(13), 1635-1701.

Downloads

Published

2017-11-01

How to Cite

Vdovichenko, V. I., & Kulchytskyi, V. V. (2017). THE INFLUENCE OF COMPETITION DRUGS FOR THE TREATMENT OF HYPERTENSION IN PATIENTS WITH TYPE 2 DIABETES. Bulletin of Scientific Research, (3). https://doi.org/10.11603/2415-8798.2017.3.8089

Issue

No. 3 (2017)

Section

INTERNAL MEDICINE

License

Authors who sent their manuscript to "Вісник наукових досліджень. Bulletin of Scientific Research" Surgery agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. Результат пошуку зображень за запитом "CC-BY logo"         

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)